Jan 20, 2026 12:30PM Corvus Pharmaceuticals (CRVS) PT Raised to $20 at Mizuho, Top January Pick

Dec 11, 2025 06:52AM Corvus Pharmaceuticals' (CRVS) Demonstrates Improvements in EASI - Cantor Fitzgerald

Nov 4, 2025 04:17PM Corvus Pharmaceuticals, Inc. (CRVS) Tops Q3 EPS by 1c

Oct 13, 2025 05:30AM Barclays Starts Corvus Pharmaceuticals (CRVS) at Overweight

Aug 7, 2025 04:13PM Corvus Pharmaceuticals, Inc. (CRVS) Tops Q2 EPS by 3c

Jun 25, 2025 08:02AM Corvus Pharma (CRVS) Announces Partner Angel Pharmaceuticals Received IND Approval for a Phase 1b/2 Clinical Trial of Soquelitinib in China for the Treatment of Atopic Dermatitis

Jun 25, 2025 06:36AM Mizuho Reiterates Outperform Rating on Corvus Pharmaceuticals (CRVS)

Jun 12, 2025 07:23AM Cantor Fitzgerald Reiterates Overweight Rating on Corvus Pharmaceuticals (CRVS)

Jun 4, 2025 07:01AM Corvus Pharma (CRVS) Announces Full Data from Cohort 3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

May 20, 2025 05:33AM Corvus Pharmaceuticals (CRVS) PT Lowered to $11 at Mizuho

May 12, 2025 05:59AM Increasing unusual option volume: CYH CNH PHAT MUB AXL DJX PSEC AVPT CRVS

May 8, 2025 04:14PM Corvus Pharma (CRVS) Announces Data from Cohorts 1-3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

May 8, 2025 04:03PM Corvus Pharmaceuticals, Inc. (CRVS) Misses Q1 EPS by 1c

Apr 9, 2025 04:02PM Corvus Pharma (CRVS) Appoints Richard A. van den Broek to Board of Directors

Mar 26, 2025 06:49AM H.C. Wainwright Reiterates Buy Rating on Corvus Pharmaceuticals (CRVS)

Mar 25, 2025 04:01PM Corvus Pharmaceuticals, Inc. (CRVS) Misses Q4 EPS by 6c

Mar 20, 2025 08:03AM Corvus Pharma (CRVS) Announces Presentation of Additional Data from the Phase 1/1b Clinical Trial of Soquelitinib for Patients with T Cell Lymphoma

Mar 12, 2025 08:01AM Corvus Pharma (CRVS) Announces Initiation of Phase 2 Clinical Trial of Soquelitinib for Patients with Autoimmune Lymphoproliferative Syndrome

Jan 13, 2025 07:30AM Corvus Pharma (CRVS) Announces Data from Cohort 2 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

Dec 23, 2024 05:34AM Increasing unusual call option volume: QUBT XND AMCR CRVS MVST ARQT AMTM CNC CE JCI

Dec 19, 2024 06:38AM Mizuho Reiterates Outperform Rating on Corvus Pharmaceuticals (CRVS)

Dec 18, 2024 08:08AM Oppenheimer Reiterates Corvus Pharmaceuticals (CRVS) at Outperform, 'anticipate the stock will move higher on this news'

Dec 18, 2024 07:33AM Corvus Pharma (CRVS) Falls 15% Following Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

Dec 18, 2024 07:30AM Corvus Pharma (CRVS) Announces Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib

Dec 17, 2024 04:49PM After-hours movers: MasterCard, Lamb Weston, CommScope and more

Dec 17, 2024 04:01PM Corvus Pharma (CRVS) to Announce Interim Data from Phase 1 Trial of Soquelitinib

Dec 4, 2024 04:06PM Corvus Pharma (CRVS) Announces Publication of Biochemistry and Preclinical Data Demonstrating Potential of ITK Inhibition with Soquelitinib

Nov 14, 2024 10:01AM Corvus Pharma (CRVS) Announces New Preclinical Data Highlighting Potential of Soquelitinib

Nov 13, 2024 01:24PM Corvus Pharmaceuticals (CRVS) PT Raised to $13 at Jefferies

Nov 12, 2024 04:03PM Corvus Pharmaceuticals, Inc. (CRVS) Misses Q3 EPS by 49c

Oct 22, 2024 06:05AM Mizuho Upgrades Corvus Pharmaceuticals (CRVS) to Outperform

Sep 16, 2024 06:48AM Corvus Pharmaceuticals (CRVS) PT Raised to $21 at Ladenburg Thalmann

Sep 10, 2024 08:31AM Corvus Pharma (CRVS) Initiates Registrational Phase 3 Clinical Trial of Soquelitinib for Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma

Aug 16, 2024 02:59PM Mizuho Reiterates Neutral Rating on Corvus Pharmaceuticals (CRVS)

Aug 6, 2024 04:05PM Corvus Pharmaceuticals, Inc. (CRVS) Tops Q2 EPS by 5c

Aug 1, 2024 08:30AM Corvus Pharma (CRVS) Granted FDA Fast Track Designation for Soquelitinib

Jul 25, 2024 08:34AM Corvus Pharma (CRVS): Publication of Preclinical Data in Science Signaling Demonstrated the Potential of ITK Inhibition with Soquelitinib as a Novel Approach to Treatment of Inflammatory Diseases